[Pubmed] Clinical effect of different immunosuppressive treatment regimens in children with ocular myasthenia gravis: a

[RSS-Bot]

Zhongguo Dang Dai Er Ke Za Zhi. 2023 Oct 15;25(10):1034-1039. doi: 10.7499/j.issn.1008-8830.2305114.

ABSTRACT

OBJECTIVES: To investigate the clinical effect of different immunosuppressive treatment regimens in children with ocular myasthenia gravis (OMG).

METHODS: A retrospective analysis was conducted on 130 children with OMG who were treated in the Department of Neurology, Jiangxi Children's Hospital, from February 2018 to February 2023. According to the treatment regimen, they were divided into four groups: glucocorticoid (GC) group (n=29), mycophenolate mofetil (MMF) group (GC+MMF; n=33), methotrexate (MTX) group (GC+MTX; n=30), and tacrolimus (FK506) group (GC+FK506; n=38). Treatment outcomes and adverse reactions were compared among the groups.

RESULTS: After 3 months of treatment, the FK506 group had significantly lower scores of Myasthenia Gravis Quantitative Scale and Myasthenia Gravis-Specific Activities of Daily Living than the other three groups (P

Source: https://pubmed.ncbi.nlm.nih.gov/3790576 ... t6+86293ac